指南与共识血栓与止血

2023年国际血栓与止血学会(ISTH)对2022年ISTH新冠肺炎抗血栓治疗指南的更新

2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19.
指南 / 共识 · J Thromb Haemost · 2024-03-18

基于新冠肺炎大流行期间的新证据,ISTH对2022年指南进行更新,采用美国心脏病学会基金会/美国心脏协会方法学评估证据级别(LOE)和推荐类别(COR),新增至少16项随机对照试验证据,共形成19条推荐,其中5条证据级别升级为A,新增2条关于抗血栓治疗的推荐,并增加疫苗接种与疫苗诱导免疫性血栓性血小板减少症(VITT)章节。

要点

  • 非重症住院新冠肺炎患者推荐使用预防剂量低分子肝素或普通肝素(强推荐,COR 1)。
  • 该组部分患者推荐治疗剂量低分子肝素/普通肝素优于预防剂量(强推荐,COR 1)。
  • 住院非重症患者不推荐加用抗血小板药物(强推荐反对,COR 3)。

核心结论

  • 更新后的ISTH指南针对新冠肺炎患者抗血栓治疗形成19条推荐,其中5条证据级别升级为A,新增2条抗血栓治疗推荐,并新增疫苗接种与VITT章节。

研究设计与样本

  • 国际血栓与止血学会(ISTH)基于2022年指南发布后至少16项新的随机对照试验证据进行更新,采用美国心脏病学会基金会/美国心脏协会方法学评估证据级别(LOE)和推荐类别(COR)。

主要发现

  • 共19条推荐:非住院患者4条,非重症住院患者5条,重症住院患者3条,出院后患者2条,疫苗接种与VITT 5条;仅纳入证据级别A或B的推荐。
  • 5条推荐的证据级别升级为A,新增2条关于新冠肺炎患者抗血栓治疗的推荐。

关键数值与推荐

  • 对非重症住院新冠肺炎患者,推荐使用预防剂量低分子肝素或普通肝素(强推荐,COR 1)。
  • 对该组部分患者,推荐治疗剂量低分子肝素/普通肝素优于预防剂量(强推荐,COR 1)。
  • 对住院非重症患者,不推荐加用抗血小板药物(强推荐反对,COR 3)。
  • 诊断VITT推荐使用抗血小板因子4酶免疫测定(强推荐,COR 1)。

临床怎么用

  • 这些国际指南为医疗资源和新冠疫苗可及性不同的国家提供推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least 16 new randomized controlled trials have contributed additional evidence, which necessitated a modification of most of the previous recommendations. We used again the American College of Cardiology Foundation/American Heart Association methodology for assessment of level of evidence (LOE) and class of recommendation (COR). Five recommendations had the LOE upgraded to A and 2 new recommendations on antithrombotic treatment for patients with COVID-19 were added. Furthermore, a section was added to answer questions about COVID-19 vaccination and vaccine-induced immune thrombotic thrombocytopenia (VITT), for which studies have provided some evidence. We only included recommendations with LOE A or B. Panelists agreed on 19 recommendations, 4 for nonhospitalized, 5 for noncritically ill hospitalized, 3 for critically ill hospitalized, and 2 for postdischarge patients, as well as 5 for vaccination and VITT. A strong recommendation (COR 1) was given for (a) use of prophylactic dose of low-molecular-weight heparin or unfractionated heparin in noncritically ill patients hospitalized for COVID-19, (b) for select patients in this group, use of therapeutic-dose low-molecular-weight heparin/unfractionated heparin in preference to prophylactic dose, and (c) for use of antiplatelet factor 4 enzyme immunoassays for diagnosing VITT. A strong recommendation was given against (COR 3) the addition of an antiplatelet agent in hospitalized, noncritically ill patients. These international guidelines provide recommendations for countries with diverse healthcare resources and COVID-19 vaccine availability.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Schulman S, Arnold DM, Bradbury CA, et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2024. PMID: 38503600. doi:10.1016/j.jtha.2024.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。